| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, 2 Merck & Co., Inc., Rahway, NJ, and 3 Merck & Co., Inc., West Point, PA, USA.
CORRESPONDENCE: M. Peters-Golden, 6301 MSRB III, 1150 W. Medical Center Drive, Ann Arbor, MI 48109-0642, USA. Fax: 1 7347644556. E-mail: petersm{at}med.umich.edu
Keywords: Asthma, beclomethasone, body mass index, inhaled corticosteroid, leukotriene antagonist, montelukast
Received: July 1, 2005
Accepted November 4, 2005
The incidence of asthma has been positively associated with obesity. Asthma comprises diverse "phenotypes" reflecting heterogeneity in a number of characteristics, including response to therapy. The present authors examined whether body mass index (BMI) influenced the response to placebo, as well as to two asthma controller medications.
A post hoc analysis was performed, pooling data from four double-blind, placebo-controlled studies randomising 3,073 moderate asthmatic adults to montelukast (n = 1,439), beclomethasone (n = 894) or placebo (n = 740). The primary end point was asthma control days; other end points were forced expiratory volume in one second, ß-agonist use and nocturnal awakening. Analyses were conducted using BMI classification into normal (<25.0 kg·m–2; 52% of patients), overweight (25–29.9 kg·m–2; 32%) and obese (
The treatment groups were balanced for BMI, demographic characteristics and parameters of asthma control. The placebo response for all end points was generally lower with increasing BMI. Similarly, the response to the inhaled corticosteroid decreased, whereas the response to the leukotriene antagonist remained stable.
In conclusion, post hoc data from the present study suggested that body mass index may influence the natural history of asthma control (as reflected by response to placebo) and may differentially influence response to the two active agents, warranting explicit testing in future prospective studies.
30.0 kg·m–2; 16%) categories, as well as BMI as a continuous variable.
This article has been cited by other articles:
|
|
 |
|
  T. J. T. Sutherland, J. O. Cowan, and D. R. Taylor Dynamic Hyperinflation with Bronchoconstriction: Differences between Obese and Nonobese Women with Asthma Am. J. Respir. Crit. Care Med., May 1, 2008; 177(9): 970 - 975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. A. Hanania Targeting Airway Inflammation in Asthma: Current and Future Therapies Chest, April 1, 2008; 133(4): 989 - 998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B Taylor, D Mannino, C Brown, D Crocker, N Twum-Baah, and F Holguin Body mass index and asthma severity in the National Asthma Survey Thorax, January 1, 2008; 63(1): 14 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Peters-Golden and W. R. Henderson Jr. Leukotrienes N. Engl. J. Med., November 1, 2007; 357(18): 1841 - 1854. [Full Text] [PDF]
|
|
|
|
|
|
R. A. Johnston, M. Zhu, Y. M. Rivera-Sanchez, F. L. Lu, T. A. Theman, L. Flynt, and S. A. Shore Allergic Airway Responses in Obese Mice Am. J. Respir. Crit. Care Med., October 1, 2007; 176(7): 650 - 658. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Alakhras, P. A. Decker, H. F. Nadrous, M. Collazo-Clavell, and J. H. Ryu Body Mass Index and Mortality in Patients With Idiopathic Pulmonary Fibrosis Chest, May 1, 2007; 131(5): 1448 - 1453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Beuther and E. R. Sutherland Overweight, Obesity, and Incident Asthma: A Meta-analysis of Prospective Epidemiologic Studies Am. J. Respir. Crit. Care Med., April 1, 2007; 175(7): 661 - 666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Shore Obesity and asthma: lessons from animal models J Appl Physiol, February 1, 2007; 102(2): 516 - 528. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.D.H. Malnick and H. Knobler The medical complications of obesity QJM, September 1, 2006; 99(9): 565 - 579. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
